Leiden

• Study to assess the effects of oral cannabidiol in healthy male subjects on CNS using the NeuroCart test battery and TMS. Ended
  2023-508311-23-00 4 2023-11-20 Neurological assessments
• Routine versus selective protamine administration to reduce bleeding complications after transcatheter aortic valve implantation Ended
  2023-504205-36-00 11 2023-11-01 Aortic stenosis
• A randomized, double-blind, double dummy, placebo-controlled, four-way cross-over study to investigate the analgesic effects and CNS effects … Ended
  2023-505793-15-00 3 2023-10-30 Chronic pain
• SAD and MAD study of VES001 Ended
  2023-505847-38-00 1 2023-10-11 Frontotemporal dementia (FTD)
• A Trial Investigating the pain-relieving properties of Lu AG06474 in Healthy Adult Participants Ended
  2023-503987-18-00 3 2023-10-03 Pain
• A Phase 1 Study of PRT3789 in Participants with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation Ended
  2022-502850-14-00 1 2023-09-25 gastroesophageal junction
• Comparison of multiple doses of intramuscular versus intranasal naloxone for reversal of opioid toxicity Ended
  2023-505338-93-00 4 2023-09-21 Healthy volunteers
• Evaluation of sensory testing to measure the effects of tetrodotoxin Ended
  2022-500318-24-00 4 2023-08-30 pain
• PREPARE-iVAC Ended
  2023-503894-39-00 11 2023-08-22 kidney transplantation
• A study of the safety of the new investigational drug CVN293 in healthy volunteers, and how CVN293 is taken up and processed by the human bo … Ended
  2023-506114-49-00 1 2023-08-15 Neurodegenerative disorders
• Hypoxic ventilatory response (HVR): Effect of Esketamine Ended
  2023-504229-37-00 6 2023-08-04 healthy volunteers
• SAD and MAD of VENT-02 in healthy volunteers Ended
  2023-505546-26-00 1 2023-07-21 Neuroinflammatory and neurodegenerative diseases
• Effect of a pain killer on breathing and another drug that stimulates breathing Ended
  2023-503912-34-00 11 2023-07-19 none, healthy subjects only
• Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis Ended
  2023-506046-24-00 4 2023-07-03 Ulcerative Colitis (UC)
• A Phase 2, Single-Blind, Placebo-Controlled Trial to Evaluate the Photoparoxysmal Electroencephalogram Response, Safety, Tolerability, and P … Ended
  2023-504803-10-00 4 2023-06-15 IPS induced photoparoxysmal electroencephalogram response (IPS-induced
• MERCURI-2 Ended
  2024-515260-31-00 6 2023-06-09 AKI
• Transcranial Magnetic Stimulation (TMS) Evaluation of Central Nervous System (CNS) Pharmacodynamic (PD) Activity of Brexanolone in Healthy M … Ended
  2022-503019-40-00 3 2023-05-11 NA, PD study in Healthy Volunteers
• Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients with Mild-to-Moderate Ulcerative Colitis Ended
  2024-512558-40-00 4 2023-05-11 Mild-to-moderate ulcerative colitis
• Neo-adjuvant Pembrolizumab in vulvar squamous cell carcinoma: a clinical proof-of-concept study Ended
  2024-512862-32-00 4 2023-05-11 Vulvar squamous cell carcinoma
• A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in th … Ended
  2022-500121-33-01 5 2023-05-08 Anti-GBM antibody disease (Goodpasture disease)
• Safety, tolerability and effect of DLX-001 in healthy volunteers Ended
  2023-503390-38-00 1 2023-04-14 Unipolar depression (UD)
• A Randomized, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Single And Multiple Ascending Dose Study To Evaluate Safety, Tolerabilit … Ended
  2024-512987-74-00 3 2023-02-27 Disorders characterized by a deficit in GABAergic signaling and cerebe
• A study investigating the safety, tolerability, absorption, excretion and effects of a new drug for the treatment of epilepsy. Ended
  2022-502638-17-00 3 2023-02-03 Epilepsy
• A Phase 2, Open-Label, Adaptive, Dose-Ranging Study with Long-Term Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokin … Ended
  2023-507328-22-00 4 2022-12-20 Tenosynovial Giant Cell Tumor

Showing 385–408 of 450 trials